Avila presented summary results in the first-in-human study kinase inhibitors, AVL-292-001, at the Keystone Symposium on Molecular together with Cellular Biology: Evolving Ways to Early-Stage Drug Discovery. Clinical development of AVL-292 may be supported, in part, through an alliance with The Leukemia & Lymphoma Modern culture (LLS). “Over 50 healthy volunteers participated in these two
(Read More…)
Boehringer Ingelheim has marked a brand new milestone within its quickly growing oncology portfolio using the announcement today that the organization has advanced another of their oncology compounds into pivotal phase III clinical development. The 2 studies, referred to as LUME-Lung 1 and LUME-Lung 2, for Vargatef? (BIBF 1120), a triple angiokinase kinase inhibitor, will
(Read More…)
TargeGen, Corporation. introduced that the organization has effectively completed a 59 patient, multicenter medical trial of TG101348, an dental, potent, and highly selective Kinase inhibitor of JAK2 in patients with myelofibrosis. You will find no presently approved specific treatments for myelofibrosis (MF), polycythemia vera (PV), or essential thrombocythemia (ET), which with each other constitute the
(Read More…)
Follow @selleckchem on twitter.
